{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T12:11:00Z","timestamp":1773403860458,"version":"3.50.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Chong Kun Dang"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Histone deacetylase inhibitors (HDACIs) have distinctive epigenetic targets involved in hepatocarcinogenesis and chemoresistance. A recent phase I\/II study reported the possibility of HDACI as a chemosensitizer in sorafenib-resistant patients. In this study, we evaluated whether CKD-5, a novel pan-HDACI, can potentiate the efficacy of sorafenib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The anticancer effect of CKD-5 with and without sorafenib was evaluated in vitro using an MTS assay with human HCC cells (SNU-3058 and SNU-761) under both normoxic and hypoxic conditions. Microarray analysis was performed to investigate the mechanism of cell death, which was also evaluated by small interfering RNA (siRNA) transfection and subsequent immunoblot assays. In vivo experiments were conducted using two different murine HCC models. C3H mice implanted with MH134 cells and C57BL\/6 mice implanted with RIL-175 cells were treated with weekly CKD-5 with and without sorafenib for 2\u2009weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>CKD-5 treatment significantly suppressed human HCC cell growth in both normoxic and hypoxic conditions. Microarray analysis and real-time PCR showed that CKD-5 treatment significantly increased peripherin expression in HCC cells and that downregulation of peripherin by siRNA decreased CKD-5-induced apoptosis. The combination of CKD-5 and sorafenib decreased cell viability more effectively than sorafenib or CKD-5 monotherapy in human and murine HCC cells. The effectiveness of the combination therapy was consistently demonstrated in the animal models. Histological and biochemical analyses demonstrated good tolerance of CKD-5 plus sorafenib in vivo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>CKD-5 may enhance sorafenib efficacy through epigenetic regulation. The combination of CKD-5 and sorafenib might be a novel therapeutic option for the treatment of HCC.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12885-020-07471-3","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T07:02:59Z","timestamp":1602745379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma"],"prefix":"10.1186","volume":"20","author":[{"given":"Young","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun Bin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Ju","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su Jong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Hwan","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"issue":"6","key":"7471_CR1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"7471_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25\u201334.","journal-title":"Lancet Oncol"},{"issue":"2","key":"7471_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1872-034X.2012.01113.x","volume":"43","author":"A Gauthier","year":"2013","unstructured":"Gauthier A, Ho M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: an update. Hepatol Res. 2013;43(2):147\u201354.","journal-title":"Hepatol Res"},{"issue":"2","key":"7471_CR4","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1148\/radiol.2015150667","volume":"279","author":"JF Geschwind","year":"2016","unstructured":"Geschwind JF, Kudo M, Marrero JA, Venook AP, Chen XP, Bronowicki JP, Dagher L, Furuse J, Ladron de Guevara L, Papandreou C, et al. TACE treatment in patients with Sorafenib-treated Unresectable hepatocellular carcinoma in clinical practice: final analysis of GIDEON. Radiology. 2016;279(2):630\u201340.","journal-title":"Radiology"},{"issue":"2","key":"7471_CR5","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1148\/radiol.2018171541","volume":"287","author":"Z Peng","year":"2018","unstructured":"Peng Z, Chen S, Wei M, Lin M, Jiang C, Mei J, Li B, Wang Y, Li J, Xie X, et al. Advanced recurrent hepatocellular carcinoma: treatment with Sorafenib alone or in combination with Transarterial chemoembolization and radiofrequency ablation. Radiology. 2018;287(2):705\u201314.","journal-title":"Radiology"},{"issue":"2","key":"7471_CR6","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1148\/radiol.2015142481","volume":"277","author":"DP Cosgrove","year":"2015","unstructured":"Cosgrove DP, Reyes DK, Pawlik TM, Feng AL, Kamel IR, Geschwind JF. Open-label single-arm phase II trial of Sorafenib therapy with drug-eluting bead Transarterial chemoembolization in patients with Unresectable hepatocellular carcinoma: clinical results. Radiology. 2015;277(2):594\u2013603.","journal-title":"Radiology"},{"issue":"19","key":"7471_CR7","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2010.1672","volume":"304","author":"GK Abou-Alfa","year":"2010","unstructured":"Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, Leung T, Gansukh B, Saltz LB. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA. 2010;304(19):2154\u201360.","journal-title":"JAMA"},{"issue":"10","key":"7471_CR8","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1634\/theoncologist.2017-0168","volume":"22","author":"Y Patt","year":"2017","unstructured":"Patt Y, Rojas-Hernandez C, Fekrazad HM, Bansal P, Lee FC. Phase II trial of Sorafenib in combination with Capecitabine in patients with hepatocellular carcinoma: INST 08-20. Oncologist. 2017;22(10):1158\u2013e1116.","journal-title":"Oncologist"},{"issue":"1","key":"7471_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.hemonc.2013.11.003","volume":"7","author":"N Naqi","year":"2014","unstructured":"Naqi N, Ahmad S, Murad S, Khattak J. Efficacy and safety of sorafenib-gemcitabine combination therapy in advanced hepatocellular carcinoma: an open-label phase II feasibility study. Hematol Oncol Stem Cell Ther. 2014;7(1):27\u201331.","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"2","key":"7471_CR10","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00280-017-3241-9","volume":"79","author":"GK Abou-Alfa","year":"2017","unstructured":"Abou-Alfa GK, Yen CJ, Hsu CH, O'Donoghue J, Beylergil V, Ruan S, Pandit-Taskar N, Gansukh B, Lyashchenko SK, Ma J, et al. Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC). Cancer Chemother Pharmacol. 2017;79(2):421\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"7471_CR11","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.dld.2017.01.146","volume":"49","author":"L Turcios","year":"2017","unstructured":"Turcios L, Vilchez V, Acosta LF, Poyil P, Butterfield DA, Mitov M, Marti F, Gedaly R. Sorafenib and FH535 in combination act synergistically on hepatocellular carcinoma by targeting cell bioenergetics and mitochondrial function. Dig Liver Dis. 2017;49(6):697\u2013704.","journal-title":"Dig Liver Dis"},{"issue":"16","key":"7471_CR12","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1158\/1078-0432.CCR-16-3171","volume":"23","author":"AG Duffy","year":"2017","unstructured":"Duffy AG, Ma C, Ulahannan SV, Rahma OE, Makarova-Rusher O, Cao L, Yu Y, Kleiner DE, Trepel J, Lee MJ, et al. Phase I and preliminary phase II study of TRC105 in combination with Sorafenib in hepatocellular carcinoma. Clin Cancer Res. 2017;23(16):4633\u201341.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"7471_CR13","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1158\/1078-0432.CCR-08-2785","volume":"15","author":"HM Prince","year":"2009","unstructured":"Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res. 2009;15(12):3958\u201369.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"7471_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1172\/JCI69738","volume":"124","author":"AC West","year":"2014","unstructured":"West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014;124(1):30\u20139.","journal-title":"J Clin Invest"},{"issue":"6","key":"7471_CR15","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.jhep.2012.01.009","volume":"56","author":"A Lachenmayer","year":"2012","unstructured":"Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y, Villanueva A, Minguez B, Tsai HW, Ward SC, Thung S, et al. Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol. 2012;56(6):1343\u201350.","journal-title":"J Hepatol"},{"issue":"19 Supplement","key":"7471_CR16","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1158\/1538-7445.AM2014-1695","volume":"74","author":"C Lee","year":"2014","unstructured":"Lee C, Ahn K-S, Jung WJ, Koh Y, Kim HJ, Lee HJ, Yoon H-J, Yoon S-S. Abstract 1695: CKD-581, a novel histone deacetylase inhibitor, synergistically enhances Bortezomib cytotoxicity in multiple myeloma cells. Cancer Res. 2014;74(19 Supplement):1695.","journal-title":"Cancer Res"},{"key":"7471_CR17","doi-asserted-by":"publisher","first-page":"S642","DOI":"10.1016\/S0959-8049(11)72473-X","volume":"47","author":"MJ Kim","year":"2011","unstructured":"Kim MJ, Lee CS, Lee DH, Yang HM, Lim IT, Bae DI, Choe YJ, Kim DH, Kim SK, Lee SS. 9208 POSTER activity of CKD-581, histone Deacetylase inhibitor, in cutaneous T-cell lymphoma models. Eur J Cancer. 2011;47:S642.","journal-title":"Eur J Cancer"},{"issue":"8 Supplement","key":"7471_CR18","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1158\/1538-7445.AM10-5435","volume":"70","author":"MJ Kim","year":"2010","unstructured":"Kim MJ, Lee CS, Han BH, Yang H-M, Lee KJ, Kim S-M, Oh HT, Lim I-T, Shin H, Bae D, et al. abstract 5435: a novel HDAC inhibitor, CKD-581, demonstrates a potent <em>in vivo<\/em> efficacy in various human tumor xenograft models. Cancer Res. 2010;70(8 Supplement):5435.","journal-title":"Cancer Res"},{"issue":"5","key":"7471_CR19","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s10637-018-0582-0","volume":"36","author":"H Cho","year":"2018","unstructured":"Cho H, Yoon DH, Kim KP, Bae KS, Kim WS, Eom HS, Kim JS, Hong JY, Kim SJ, Lee H, et al. Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy. Investig New Drugs. 2018;36(5):877\u201385.","journal-title":"Investig New Drugs"},{"issue":"9","key":"7471_CR20","first-page":"3858","volume":"42","author":"H Nakabayashi","year":"1982","unstructured":"Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res. 1982;42(9):3858\u201363.","journal-title":"Cancer Res"},{"issue":"4","key":"7471_CR21","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3748\/wjg.v5.i4.289","volume":"5","author":"JH Lee","year":"1999","unstructured":"Lee JH, Ku JL, Park YJ, Lee KU, Kim WH, Park JG. Establishment and characterization of four human hepatocellular carcinoma cell lines containing hepatitis B virus DNA. World J Gastroenterol. 1999;5(4):289\u201395.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"7471_CR22","first-page":"1005","volume":"61","author":"YI Yamashita","year":"2001","unstructured":"Yamashita YI, Shimada M, Hasegawa H, Minagawa R, Rikimaru T, Hamatsu T, Tanaka S, Shirabe K, Miyazaki JI, Sugimachi K. Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model. Cancer Res. 2001;61(3):1005\u201312.","journal-title":"Cancer Res"},{"issue":"3","key":"7471_CR23","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/ijc.2910620308","volume":"62","author":"JG Park","year":"1995","unstructured":"Park JG, Lee JH, Kang MS, Park KJ, Jeon YM, Lee HJ, Kwon HS, Park HS, Yeo KS, Lee KU, et al. Characterization of cell lines established from human hepatocellular carcinoma. Int J Cancer. 1995;62(3):276\u201382.","journal-title":"Int J Cancer"},{"issue":"11","key":"7471_CR24","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00109-002-0380-0","volume":"80","author":"KR Kim","year":"2002","unstructured":"Kim KR, Moon HE, Kim KW. Hypoxia-induced angiogenesis in human hepatocellular carcinoma. J Mol Med (Berl). 2002;80(11):703\u201314.","journal-title":"J Mol Med (Berl)"},{"key":"7471_CR25","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.biopha.2016.07.027","volume":"83","author":"Y Cho","year":"2016","unstructured":"Cho Y, Cho EJ, Lee JH, Yu SJ, Kim YJ, Kim CY, Yoon JH. Fucoidan-induced ID-1 suppression inhibits the in vitro and in vivo invasion of hepatocellular carcinoma cells. Biomed Pharmacother. 2016;83:607\u201316.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"7471_CR26","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1053\/j.gastro.2006.09.014","volume":"131","author":"JM Llovet","year":"2006","unstructured":"Llovet JM, Chen Y, Wurmbach E, Roayaie S, Fiel MI, Schwartz M, Thung SN, Khitrov G, Zhang W, Villanueva A, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology. 2006;131(6):1758\u201367.","journal-title":"Gastroenterology"},{"issue":"7","key":"7471_CR27","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/labinvest.2015.60","volume":"95","author":"H Saijo","year":"2015","unstructured":"Saijo H, Tatsumi N, Arihiro S, Kato T, Okabe M, Tajiri H, Hashimoto H. Microangiopathy triggers, and inducible nitric oxide synthase exacerbates dextran sulfate sodium-induced colitis. Lab Investig. 2015;95(7):728\u201348.","journal-title":"Lab Investig"},{"issue":"Pt 15","key":"7471_CR28","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1242\/jcs.059113","volume":"123","author":"WT Clarke","year":"2010","unstructured":"Clarke WT, Edwards B, McCullagh KJ, Kemp MW, Moorwood C, Sherman DL, Burgess M, Davies KE. Syncoilin modulates peripherin filament networks and is necessary for large-calibre motor neurons. J Cell Sci. 2010;123(Pt 15):2543\u201352.","journal-title":"J Cell Sci"},{"key":"7471_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12950-019-0216-0","volume":"16","author":"X Li","year":"2019","unstructured":"Li X, Duan L, Yuan S, Zhuang X, Qiao T, He J. Ferroptosis inhibitor alleviates radiation-induced lung fibrosis (RILF) via down-regulation of TGF-beta1. J Inflamm (Lond). 2019;16:11.","journal-title":"J Inflamm (Lond)"},{"issue":"1","key":"7471_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1177\/030006059902700104","volume":"27","author":"S Nakatani","year":"1999","unstructured":"Nakatani S, Iwagaki H, Okabayashi T, Matsubara N, Isozaki H, Takakura N, Horimi T, Tanaka N. Effects of streptococcal preparation OK-432 on cytokine induction in spleen and tumour tissues of mice bearing MH-134 tumour cells. J Int Med Res. 1999;27(1):27\u201337.","journal-title":"J Int Med Res"},{"issue":"5","key":"7471_CR31","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jhep.2017.12.025","volume":"68","author":"LA Orci","year":"2018","unstructured":"Orci LA, Lacotte S, Delaune V, Slits F, Oldani G, Lazarevic V, Rossetti C, Rubbia-Brandt L, Morel P, Toso C. Effects of the gut-liver axis on ischaemia-mediated hepatocellular carcinoma recurrence in the mouse liver. J Hepatol. 2018;68(5):978\u201385.","journal-title":"J Hepatol"},{"issue":"1","key":"7471_CR32","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.radonc.2008.10.015","volume":"91","author":"H Hou","year":"2009","unstructured":"Hou H, Lariviere JP, Demidenko E, Gladstone D, Swartz H, Khan N. Repeated tumor pO(2) measurements by multi-site EPR oximetry as a prognostic marker for enhanced therapeutic efficacy of fractionated radiotherapy. Radiother Oncol. 2009;91(1):126\u201331.","journal-title":"Radiother Oncol"},{"issue":"2","key":"7471_CR33","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1080\/19466315.2018.1437071","volume":"10","author":"Q Liu","year":"2018","unstructured":"Liu Q, Yin X, Languino LR, Altieri DC. Evaluation of drug combination effect using a bliss independence dose-response surface model. Stat Biopharm Res. 2018;10(2):112\u201322.","journal-title":"Stat Biopharm Res"},{"issue":"Suppl 1","key":"7471_CR34","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1159\/000481244","volume":"93","author":"M Kudo","year":"2017","unstructured":"Kudo M. Systemic Therapy for Hepatocellular Carcinoma: 2017 Update. Oncology. 2017;93(Suppl 1):135\u201346.","journal-title":"Oncology"},{"issue":"21","key":"7471_CR35","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","volume":"25","author":"EA Olsen","year":"2007","unstructured":"Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(21):3109\u201315.","journal-title":"J Clin Oncol"},{"issue":"29","key":"7471_CR36","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","volume":"28","author":"SJ Whittaker","year":"2010","unstructured":"Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28(29):4485\u201391.","journal-title":"J Clin Oncol"},{"issue":"12","key":"7471_CR37","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1158\/1078-0432.CCR-14-3119","volume":"21","author":"HZ Lee","year":"2015","unstructured":"Lee HZ, Kwitkowski VE, Del Valle PL, Ricci MS, Saber H, Habtemariam BA, Bullock J, Bloomquist E, Li Shen Y, Chen XH, et al. FDA approval: Belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Clin Cancer Res. 2015;21(12):2666\u201370.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"7471_CR38","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-15-0530","volume":"21","author":"JP Laubach","year":"2015","unstructured":"Laubach JP, Moreau P, San-Miguel JF, Richardson PG. Panobinostat for the treatment of multiple myeloma. Clin Cancer Res. 2015;21(21):4767\u201373.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"7471_CR39","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1158\/0008-5472.CAN-10-2430","volume":"71","author":"MJ LaBonte","year":"2011","unstructured":"LaBonte MJ, Wilson PM, Fazzone W, Russell J, Louie SG, El-Khoueiry A, Lenz HJ, Ladner RD. The dual EGFR\/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. Cancer Res. 2011;71(10):3635\u201348.","journal-title":"Cancer Res"},{"issue":"23","key":"7471_CR40","doi-asserted-by":"publisher","first-page":"11298","DOI":"10.1158\/0008-5472.CAN-06-0049","volume":"66","author":"L Geng","year":"2006","unstructured":"Geng L, Cuneo KC, Fu A, Tu T, Atadja PW, Hallahan DE. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res. 2006;66(23):11298\u2013304.","journal-title":"Cancer Res"},{"key":"7471_CR41","doi-asserted-by":"publisher","first-page":"bcr2012007576","DOI":"10.1136\/bcr-2012-007576","volume":"2012","author":"F Knieling","year":"2012","unstructured":"Knieling F, Waldner MJ, Goertz RS, Strobel D. Quantification of dynamic contrast-enhanced ultrasound in HCC: prediction of response to a new combination therapy of sorafenib and panobinostat in advanced hepatocellular carcinoma. BMJ Case Rep. 2012;2012:bcr2012007576.","journal-title":"BMJ Case Rep"},{"issue":"6","key":"7471_CR42","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1159\/000112360","volume":"6","author":"MM Portier","year":"1983","unstructured":"Portier MM, de Nechaud B, Gros F. Peripherin, a new member of the intermediate filament protein family. Dev Neurosci. 1983;6(6):335\u201344.","journal-title":"Dev Neurosci"},{"issue":"11","key":"7471_CR43","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1523\/JNEUROSCI.09-11-03766.1989","volume":"9","author":"MM Oblinger","year":"1989","unstructured":"Oblinger MM, Wong J, Parysek LM. Axotomy-induced changes in the expression of a type III neuronal intermediate filament gene. J Neurosci. 1989;9(11):3766\u201375.","journal-title":"J Neurosci"},{"issue":"1","key":"7471_CR44","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jns.2003.08.016","volume":"217","author":"CZ He","year":"2004","unstructured":"He CZ, Hays AP. Expression of peripherin in ubiquinated inclusions of amyotrophic lateral sclerosis. J Neurol Sci. 2004;217(1):47\u201354.","journal-title":"J Neurol Sci"},{"issue":"44","key":"7471_CR45","doi-asserted-by":"publisher","first-page":"45951","DOI":"10.1074\/jbc.M408139200","volume":"279","author":"F Gros-Louis","year":"2004","unstructured":"Gros-Louis F, Lariviere R, Gowing G, Laurent S, Camu W, Bouchard JP, Meininger V, Rouleau GA, Julien JP. A frameshift deletion in peripherin gene associated with amyotrophic lateral sclerosis. J Biol Chem. 2004;279(44):45951\u20136.","journal-title":"J Biol Chem"},{"issue":"3","key":"7471_CR46","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1750-3639.2004.tb00066.x","volume":"14","author":"CL Leung","year":"2004","unstructured":"Leung CL, He CZ, Kaufmann P, Chin SS, Naini A, Liem RK, Mitsumoto H, Hays AP. A pathogenic peripherin gene mutation in a patient with amyotrophic lateral sclerosis. Brain Pathol. 2004;14(3):290\u20136.","journal-title":"Brain Pathol"},{"issue":"6","key":"7471_CR47","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1053\/j.gastro.2013.08.055","volume":"145","author":"K Revill","year":"2013","unstructured":"Revill K, Wang T, Lachenmayer A, Kojima K, Harrington A, Li J, Hoshida Y, Llovet JM, Powers S. Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma. Gastroenterology. 2013;145(6):1424\u201335 e1421\u20131425.","journal-title":"Gastroenterology"},{"key":"7471_CR48","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, Clark NR, Ma'ayan A. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013;14:128.","journal-title":"BMC Bioinformatics"},{"issue":"9","key":"7471_CR49","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1158\/1078-0432.CCR-10-2156","volume":"17","author":"A Chase","year":"2011","unstructured":"Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin Cancer Res. 2011;17(9):2613\u20138.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"7471_CR50","doi-asserted-by":"publisher","first-page":"59","DOI":"10.7150\/ijbs.8.59","volume":"8","author":"KH Yoo","year":"2012","unstructured":"Yoo KH, Hennighausen L. EZH2 methyltransferase and H3K27 methylation in breast cancer. Int J Biol Sci. 2012;8(1):59\u201365.","journal-title":"Int J Biol Sci"},{"issue":"22","key":"7471_CR51","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1101\/gad.1035902","volume":"16","author":"A Kuzmichev","year":"2002","unstructured":"Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D. Histone methyltransferase activity associated with a human multiprotein complex containing the enhancer of Zeste protein. Genes Dev. 2002;16(22):2893\u2013905.","journal-title":"Genes Dev"},{"issue":"4","key":"7471_CR52","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/70602","volume":"23","author":"J van der Vlag","year":"1999","unstructured":"van der Vlag J, Otte AP. Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet. 1999;23(4):474\u20138.","journal-title":"Nat Genet"},{"issue":"49","key":"7471_CR53","doi-asserted-by":"publisher","first-page":"86168","DOI":"10.18632\/oncotarget.21030","volume":"8","author":"TP Liu","year":"2017","unstructured":"Liu TP, Hong YH, Yang PM. In silico and in vitro identification of inhibitory activities of sorafenib on histone deacetylases in hepatocellular carcinoma cells. Oncotarget. 2017;8(49):86168\u201380.","journal-title":"Oncotarget"},{"key":"7471_CR54","doi-asserted-by":"publisher","first-page":"30483","DOI":"10.1038\/srep30483","volume":"6","author":"TY Zhou","year":"2016","unstructured":"Zhou TY, Zhuang LH, Hu Y, Zhou YL, Lin WK, Wang DD, Wan ZQ, Chang LL, Chen Y, Ying MD, et al. Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells. Sci Rep. 2016;6:30483.","journal-title":"Sci Rep"},{"issue":"5","key":"7471_CR55","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1172\/JCI90253","volume":"127","author":"D Lee","year":"2017","unstructured":"Lee D, Xu IM, Chiu DK, Lai RK, Tse AP, Lan Li L, Law CT, Tsang FH, Wei LL, Chan CY, et al. Folate cycle enzyme MTHFD1L confers metabolic advantages in hepatocellular carcinoma. J Clin Invest. 2017;127(5):1856\u201372.","journal-title":"J Clin Invest"},{"issue":"5","key":"7471_CR56","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060\u201372.","journal-title":"Cell"},{"key":"7471_CR57","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.freeradbiomed.2018.09.033","volume":"133","author":"S Masaldan","year":"2019","unstructured":"Masaldan S, Bush AI, Devos D, Rolland AS, Moreau C. Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration. Free Radic Biol Med. 2019;133:221\u201333.","journal-title":"Free Radic Biol Med"},{"issue":"11","key":"7471_CR58","first-page":"6417","volume":"34","author":"E Lachaier","year":"2014","unstructured":"Lachaier E, Louandre C, Godin C, Saidak Z, Baert M, Diouf M, Chauffert B, Galmiche A. Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors. Anticancer Res. 2014;34(11):6417\u201322.","journal-title":"Anticancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07471-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07471-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07471-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T10:19:35Z","timestamp":1669198775000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07471-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7471"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07471-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"assertion":[{"value":"12 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The in vivo study protocol was approved by the Institutional Animal Care and Use Committee of Seoul National University Hospital.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1001"}}